Strategic Frameworks for Bioanalytical Method Development for POC Therapeutics Establishing robust analytical assays for peptide-oligonucleotide conjugates requires highly specialized methodologies […]
Introduction: Bioanalytical method development for mRNA therapeutics is fundamentally different from conventional drug modalities — and getting it wrong at
Introduction Developing reliable bioanalytical assays for emerging therapeutic modalities requires navigating an increasingly complex biophysical environment. When establishing analytical strategies
Introduction Within the highly specialized field of drug development, implementing advanced Bioanalytical Services for Rare Disease programs is essential for
Navigating Clinical Translation of CNS Small Molecules Under FDA Fast Track The clinical translation of central nervous system (CNS)-active small
Introduction: A bioanalytical method validation failure is one of the most operationally significant and regulatorily sensitive events in drug development.
Introduction: Disulfide Bond Mapping in Therapeutic Peptides is a critical analytical process used to verify the structural integrity and biological
Introduction: Why Tissue and CSF Bioanalysis Is the Defining Step in CNS Drug Development One of the greatest challenges in
Tissue and CSF Bioanalytical Services for CNS Drug Development Programs Read More »
Introduction: The Bioanalytical Complexity of ADC Programs Bioanalysis for an Antibody-Drug Conjugate Program is far from a straightforward analytical exercise.
Case Study: Dual Analyte LC-MS/MS Bioanalysis for an Antibody-Drug Conjugate Program Read More »
Introduction: Why CRO Selection Is a Regulatory Decision, Not Just a Scientific One When sponsors prepare regulated bioanalytical services for
Regulated Bioanalytical Services for NDA and BLA Submissions: What to Look for in a CRO Read More »
